Enanta Pharmaceuticals, Inc. (ENTA) — Stock Score Summary

Enanta Pharmaceuticals, Inc. (ENTA) has a MoatMap StockRank of 28/100 based on Quality (33/100), Value (40/100), and Momentum (42/100) factor scores. The current signal is SELL. Enanta Pharmaceuticals is a small-cap biotech company with a low quality score (Q: 33). It does not possess the validated, high-utilization manufacturing infrastructure of a true CDMO, making it a speculative drug developer rather than a high-moat gatekeeper.

Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs for viral infections and liver diseases. The company utilizes proprietary chemistry platforms and strong R&D capabilities, leading to partnerships with major pharmaceutical companies for drug development and commercialization. Enanta is a specialized biotech firm known for its expertise in infectious diseases, particularly Hepatitis C and respiratory syncytial virus (RSV).

Key Financial Metrics

Price$10.95
Market Cap$385M
P/E (Forward)-6.00
Price/Book2.92
Return on Equity-59.0%
Return on Invested Capital-32.7%
Debt/Equity160.07
Gross Margin100.0%
Operating Margin-69.1%
Revenue Growth15.0%
Free Cash Flow$8M

Enanta Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Enanta Pharmaceuticals, Inc.’s (ENTA) StockRank?
MoatMap’s StockRank for Enanta Pharmaceuticals, Inc. (ENTA) is 28/100, with a Sell signal. It is a composite of Quality (33), Value (40), and Momentum (42) factor ranks across MoatMap’s 19,000+ stock universe.
Does Enanta Pharmaceuticals, Inc. have an economic moat?
Enanta Pharmaceuticals, Inc. (ENTA) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Enanta Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Enanta Pharmaceuticals, Inc. (ENTA) is Sell, based on a StockRank of 28/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Enanta Pharmaceuticals, Inc. in?
Enanta Pharmaceuticals, Inc. (ENTA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksENTA deep dive reportAI ChampionsHow we score stocksSense-check another stock